IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance Biotherapeutics (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with Amtagvi US revenue crossing $100M. Interim CEO Vogt confirmed no impact from past maintenance issues and expects sequential growth. CFO Roche noted improved profitability. Proleukin sales rose to $20M, aligning with Amtagvi demand. LUN-202 data expected next year, with BLA submission planned for 2027. Community hospital infusions are growing, currently at 1/3 of total. Cash runway extended into 2029.

Iovance Biotherapeutics (IOVA) announced that its treatment lifileucel showed strong efficacy in advanced soft tissue sarcomas, according to a pilot study. The FDA granted lifileucel fast track designation for these sarcomas. IOVA reported Q3 2026 revenue of $121.47M and a net loss of $22.27M. The company is expanding its TIL platform beyond melanoma into other solid tumor indications.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Corporate Overview November 2026 Exhibit 99.1 Exhibit 99.1 Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meani

Iovance (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with AMTAGVI sales at $102M. The company expects to expand its ATC network to 110+ centers by year-end. Clinical trials for lifileucel in non-small cell lung cancer and sarcoma showed promising results, with FDA fast-track designations granted. Iovance plans sBLA submissions in 2027 and 2028-2029. The company's cash runway is expected to extend into 2029.

Iovance Biotherapeutics reported Q3 earnings, highlighting quarter-over-quarter growth and tracking to its annual guidance. The company has expanded its treatment network to over 100 centers in the U.S. and plans further international approvals. It is also progressing with lung cancer trials and additional pipeline programs. Chief Medical Officer Noah Berkowitz noted a 24.6% objective response rate in updated lung cancer trial results.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M , Business Achievements, and Corporate Updates Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response